(RTTNews) – Today’s daily dose brings you news about the acquisition of Momenta through JJ, the fda refuses to approve the gene therapy for BioMarin hemophilia, ThermoGenesis’s COVID-19 combo kit gets a red flag, Merck’s Keytruda KEYNOTE-590 meets the trial goals, NuCana is planned milestones and knowledge of the TRIDENT-1Array of Turning point
Read…
1. Momenta purchased through J-J for $6.5 billion
Momenta Pharmaceuticals Inc. (MNTA) is about to be acquired through Johnson and Johnson (JNJ) for $52.50 consistent with a percentage consisting of a fully monetary transaction, which is at an inventory price of $6.5 billion.
The transaction is expected to close at the time of 2020.
MNTA trades about $29 when we alert readers on January 16, 2020 (https://www.rttnews.com/3060533/momenta-pharma-mnta-up-over-60-in-a-month-key-data-readouts- in-2020.aspx)
The inventory closed Wednesday at $52.12, an increase of 69.17%.
2. BioMarin Hemophilia Gene Therapy Does Not Pass FDA Test
BioMarin had applied for approval of Valoctocogene roxaparvovec in an interim investigation of a Phase III exam comparing the efficacy and protection of Valoctocogene roxaparvovec in patients with hemophilia A and knowledge for 3 years of the Phase I/II exam.
In its full reaction letter, the regulatory firm asked the company to complete the ongoing Phase III trial that compares the efficacy and protection of Valoctocogene roxaparvovec in patients with hemophilia A and to submit two-year follow-up information on all participants.
If approved, Valoctocogene roxaparvovec would have been the first approved genetic treatment in any of the cases of hemophilia.
BMRN closed Wednesday at $76.71, down 35.28 percent.
The actions of ThermoGenesis Holdings Inc. (THMO) have lost 18% of their value since the FDA warned of a threat of false effects with the Thermo Fisher Scientific TaqPath COVID-19 combo kit on August 17.
The TaqPath COVID-19 combined kit obtained FDA emergency use approval in March this year to stumble upon SARS-CoV-2 nucleic acid, the culprit COVID-19 virus. This verification uses the generation of the Applied Biosystems TaqPath assay and is designed to provide effects to the patient within 4 hours of receiving a pattern from a laboratory.
THMO closed Wednesday’s consultation at $3.28, down 5.48 percent.
3. BioLineRx GENESIS in action
The study, called GENESIS, was presented in December 2017 and recruitment is expected to continue until the length of the pattern is reached first planned.
The Company expects the mid-term investigation to be completed in the coming months and if the number one evaluation criterion is met at the time of the mid-term investigation, the company expects to announce the completion of the next hiring, without wanting to recruit the full pattern. Expected. Size.
The main effects of the GENESIS test are expected in the first part of 2021.
BLRX closed Wednesday at $2.19, an increase of 3.79%.
The Mytesi Jaguar Health Inc. (JAGX) pilot exam on non-positive adult patients, conducted at the University of Texas Health Science Center at the University of Houston, has begun enrolling and full recruitment is expected until the end of the year. The effects of the review are expected to occur until mid-to-late 2021.
Mytesi, in December 2012, is an antidiarrheal drug indicated for symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS in antiretroviral processing (ART).
A Phase II examination is underway in Mytesi for the relief of diarrhoea symptoms in HER2-positive breast cancer patients receiving chemotherapy with trastuzumab, pertuzumab and docetaxel or paclitaxel with or without carboplatin, and test subjects are expected to have a complete remedy until the end of 2020. The final effects of this study are expected to occur until mid-2021.
One of Mytesi, initiated through a researcher, will be held at a singles center at Beth Israel Deaconess Medical Center, an establishment at Harvard Medical School in Boston, and registration is expected to begin in the fourth quarter of 2020.
5. Merck KEYNOTE-590 achieves key goals
Merck’s pivotal Phase III study comparing its successful cancer drug KEYTRUDA in combination with chemotherapy, called the KEYNOTE-590 study, met its number one criteria to assess overall survival and progression-free survival for first-line treatment of patients with metastatic esophagus or cancer.
The study also met the key secondary assessment criterion of objective reaction speed, with significant innovations for KEYTRUDA in combination with chemotherapy and chemotherapy alone.
KEYTRUDA has recently been approved in the United States and China as a monotherapy for the second-line remedy of patients with locally complex or metastatic recurrent spontaneous carcinoma of the esophagus whose tumors express PD-L1.
MRK closed Wednesday at $85.03, an increase of 0.56%.
6. NuCana prepares for a busy future
NuCana plc (NCNA) is scheduled for the rest of this year.
Corporate plans to provide more provisional clinical knowledge of the ongoing NUC-3373 Phase Ib in mix with other agents associated with 5-FU in patients with complex colorectal cancer, as well as the first clinical knowledge of the ongoing IArray Phase NUC-7738 in patients with complex tumors forged at the ESMO 2020 Virtual Congress to be held from September 19 to 21, 2020.
NCNA closed Wednesday at $5.42, up 0.37 percent.
7. Turning Point’s KNOWLEDGE of TRIDENT-1 draws attention
Turning Point Therapeutics Inc. TRIDENT-1, proved promising.
According to intermediate phase II data, the reaction shown for an objective reaction rate of 86% in the TKI ROS1 lung cancer population positive for previously untreated non-small mobile ROS1, 40% in the positive NPC ROS1 POBLATION pre-treated with previous TKI with prior chemotherapy, 67% in the population with NSCLC ROS1-positive pretreated with prior TKI without Prior Chemotherapy Array and 50% in the pre-milked tumor population NTRK TKI-positive.
TPTX closed Wednesday at $67.10, up 5.29 percent.
8. Actions that have had anything new
9 Meters Biopharma Inc. (NMTR) closed wednesday at $0.84, an increase of 29.85%.
Ontrak Inc. (OTRK) closed Wednesday at $65.33, up 22 percent.
CureVac N.V. (CVAC) closed Wednesday’s consultation at $56.90, 13.39% less.
Solid Biosciences Inc. (SLDB) closed Wednesday’s query at $2.65, up 13.11% less.